Atea Pharmaceuticals (NASDAQ:AVIR – Get Rating) had its price objective decreased by investment analysts at JPMorgan Chase & Co. from $10.00 to $8.00 in a report issued on Wednesday, Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 26.98% from the […]